Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency
In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the sa...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-12-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839574482233065472 |
|---|---|
| author | V. A. Misyurin A. V. Misyurin A. E. Misyurina Yu. P. Finashutina M. A. Baryshnikovа O. S. Burova S. K. Kravchenko |
| author_facet | V. A. Misyurin A. V. Misyurin A. E. Misyurina Yu. P. Finashutina M. A. Baryshnikovа O. S. Burova S. K. Kravchenko |
| author_sort | V. A. Misyurin |
| collection | DOAJ |
| description | In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the same. We electrophoresed formulations in denaturing conditions. Protein from formulations was denatured into fragments. Heavy and light chains of immunoglobulin were observed in gel. Finally, we performed flow cytometry where rituximab was used as primary antibody to detect CD20-positive B-cells of patients with B-cell chronic lymphocytic leukemia. Both Mabtera® and Acellbia® recognized the same number of cells. Thus, assays performed in vitro submitted identity of Mabtera® and Acellbia® characteristics. |
| format | Article |
| id | doaj-art-956f6b6bcae84a1494e866ac0b514d24 |
| institution | Matheson Library |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2015-12-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-956f6b6bcae84a1494e866ac0b514d242025-08-04T13:57:49ZrusABV-pressОнкогематология1818-83462413-40232015-12-01104565910.17650/1818-8346-2015-10-4-56-59180Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiencyV. A. Misyurin0A. V. Misyurin1A. E. Misyurina2Yu. P. Finashutina3M. A. Baryshnikovа4O. S. Burova5S. K. Kravchenko6N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; “GenoTechnology” LLCN.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; “GenoTechnology” LLC“GenoTechnology” LLC; Hematology Research Center, Ministry of Health of RussiaN.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; “GenoTechnology” LLCN.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaN.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaHematology Research Center, Ministry of Health of RussiaIn present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the same. We electrophoresed formulations in denaturing conditions. Protein from formulations was denatured into fragments. Heavy and light chains of immunoglobulin were observed in gel. Finally, we performed flow cytometry where rituximab was used as primary antibody to detect CD20-positive B-cells of patients with B-cell chronic lymphocytic leukemia. Both Mabtera® and Acellbia® recognized the same number of cells. Thus, assays performed in vitro submitted identity of Mabtera® and Acellbia® characteristics.https://oncohematology.abvpress.ru/ongm/article/view/168acellbia®mabthera®laboratory diagnosticsmonoclonal antibodie sensitivity |
| spellingShingle | V. A. Misyurin A. V. Misyurin A. E. Misyurina Yu. P. Finashutina M. A. Baryshnikovа O. S. Burova S. K. Kravchenko Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency Онкогематология acellbia® mabthera® laboratory diagnostics monoclonal antibodie sensitivity |
| title | Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency |
| title_full | Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency |
| title_fullStr | Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency |
| title_full_unstemmed | Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency |
| title_short | Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency |
| title_sort | acellbia r and mabtera r are recognize cd20 positive cells with equal efficiency |
| topic | acellbia® mabthera® laboratory diagnostics monoclonal antibodie sensitivity |
| url | https://oncohematology.abvpress.ru/ongm/article/view/168 |
| work_keys_str_mv | AT vamisyurin acellbiaandmabteraarerecognizecd20positivecellswithequalefficiency AT avmisyurin acellbiaandmabteraarerecognizecd20positivecellswithequalefficiency AT aemisyurina acellbiaandmabteraarerecognizecd20positivecellswithequalefficiency AT yupfinashutina acellbiaandmabteraarerecognizecd20positivecellswithequalefficiency AT mabaryshnikova acellbiaandmabteraarerecognizecd20positivecellswithequalefficiency AT osburova acellbiaandmabteraarerecognizecd20positivecellswithequalefficiency AT skkravchenko acellbiaandmabteraarerecognizecd20positivecellswithequalefficiency |